Pharmacogenomic Study of Androgenetic Alopecia
Launched by TAIPEI MEDICAL UNIVERSITY WANFANG HOSPITAL · Oct 21, 2010
Trial Information
Current as of July 07, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing to sign inform consent form
- • Willing to received history taking by telephone or interview
- • Diagnosed androgenetic alopecia by Hamilton-Norwood classification
- • More than 20 year-old, both sex
- Exclusion Criteria:
- • Ever had trauma over alopecia area
- • Cancer, infection, or other systemic disease that might interfere diagnosis
- • Unconfirmed diagnosis clinically or pathologically.
About Taipei Medical University Wanfang Hospital
Taipei Medical University Wan Fang Hospital is a leading healthcare institution in Taiwan, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital combines cutting-edge medical technology with a multidisciplinary approach to research, facilitating innovative studies that address critical health challenges. With a focus on ethical standards and patient safety, Wan Fang Hospital collaborates with a network of medical professionals and researchers to contribute valuable insights to the global medical community. Its dedication to excellence in clinical trials underscores its role as a pivotal player in the advancement of healthcare practices and therapeutic developments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Ren-Yu Tsai
Principal Investigator
Taipei Medical University-Wan Fang Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials